Analyzing Horizon Pharma PLC (HZNP) and Its Competitors
Horizon Pharma PLC (NASDAQ: HZNP) is one of 112 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Horizon Pharma PLC to similar businesses based on the strength of its dividends, institutional ownership, analyst recommendations, risk, profitability, earnings and valuation.
Risk & Volatility
Horizon Pharma PLC has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Horizon Pharma PLC’s rivals have a beta of 0.86, suggesting that their average stock price is 14% less volatile than the S&P 500.
This table compares Horizon Pharma PLC and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Horizon Pharma PLC||-42.40%||22.85%||6.86%|
|Horizon Pharma PLC Competitors||-3,613.41%||-52.33%||-8.32%|
Earnings & Valuation
This table compares Horizon Pharma PLC and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Horizon Pharma PLC||$1.03 billion||-$46.52 million||-4.39|
|Horizon Pharma PLC Competitors||$7.86 billion||$2.50 billion||1.27|
Horizon Pharma PLC’s rivals have higher revenue and earnings than Horizon Pharma PLC. Horizon Pharma PLC is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
82.3% of Horizon Pharma PLC shares are held by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.2% of Horizon Pharma PLC shares are held by insiders. Comparatively, 12.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and target prices for Horizon Pharma PLC and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Horizon Pharma PLC||0||2||9||0||2.82|
|Horizon Pharma PLC Competitors||942||3779||5989||164||2.49|
Horizon Pharma PLC presently has a consensus target price of $18.91, indicating a potential upside of 59.71%. As a group, “Pharmaceuticals” companies have a potential upside of 26.68%. Given Horizon Pharma PLC’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Horizon Pharma PLC is more favorable than its rivals.
Horizon Pharma PLC beats its rivals on 8 of the 12 factors compared.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company’s marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.